Oxaliplatin Injection, Solution, Concentrate
Product Images NDC 61703-363

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 61703-363). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Oxaliplatin 01)

Chemical structure of Oxaliplatin shown with two amine groups bonded to a platinum atom which is also bonded to an oxalate group. The diagram displays the molecular connectivity among these components.*

FDA Label Image

Oxaliplatin Structural Formula (Oxaliplatin 02)

A Kaplan-Meier survival curve chart showing DFS (disease-free survival) probability over time in months up to 72. It compares two treatment arms: FOLFOX4 (solid line) and LV5FU2 (dashed line), with numbers of events and patients at risk listed. The chart includes hazard ratio and p-value for statistical significance.*

FDA Label Image

Figure 2 (DFS Kaplan-Meier curves by treatment arm (cutoff: 1 June 2006))

A Kaplan-Meier survival curve chart showing Disease-Free Survival (DFS) probability over time in months, comparing two treatment arms labeled FOLFOX4 and LV5FU2. The chart includes a hazard ratio with 95% confidence interval and a logrank test p-value, indicating statistical analysis of DFS for stage II patients.*

FDA Label Image

Figure 3 (DFS Kaplan-Meier curves by treatment arm in Stage III patients (cutoff: 1 June 2006))

A survival curve chart displaying the percentage of patients surviving over a 24-month period for three treatment groups: ELOXATIN plus 5-FU/LV, ELOXATIN plus irinotecan, and irinotecan plus 5-FU/LV. The chart includes median survival times in months for each group and a statistical significance indicator (p < 0.0001) from a log-rank test comparing Eloxatin plus 5-FU/LV to irinotecan plus 5-FU/LV.*

FDA Label Image

Figure 4 (Kaplan-Meier Overall Survival by treatment arm)

FDA Label Image

Hospira Logo (Oxaliplatin 06)

FDA Label Image

Principal Display Panel (10 mL Vial Label)

Label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) sterile aqueous solution in a 10 mL single dose vial. It is indicated for intravenous use only with warnings not to dilute with sodium chloride or chloride-containing solutions. The label includes storage instructions, manufacturer information (Hospira Worldwide, Inc.), and an NDC number 61703-363-18.*

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Oxaliplatin Injection, USP 50 mg per 10 mL (5 mg/mL) sterile aqueous solution in a single-dose vial. The label features warnings for cytotoxic agent handling and storage instructions at 20-25°C with protection from light. Manufactured and distributed by Hospira Worldwide, Inc., the label includes dosage and inactive ingredient information.*

FDA Label Image

Principal Display Panel (20 mL Vial Label)

Label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) sterile aqueous solution in a 20 mL single dose vial. The label includes warnings against dilution with sodium chloride solutions and indicates use for intravenous administration. Distributed by Hospira Worldwide, Inc., Lake Forest, IL.*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Box packaging label for Oxaliplatin Injection, USP 5 mg/mL, with a total vial volume of 20 mL (100 mg total). The label indicates it is a sterile aqueous solution for intravenous use only, distributed by Hospira Worldwide, Inc. The label includes cautions about cytotoxicity and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.